All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lupus Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Visual abstract | Obinutuzumab in patients with LN: Post-hoc analyses of the phase II NOBILITY trial
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Obinutuzumab is a recombinant, humanized anti-CD20 monoclonal antibody.1 Treatment with obinutuzumab resulted in greater complete renal response at Week 52 (35% vs 23%; p = 0.115) and Week 104 (41% vs 23%; p = 0.026) in patients with lupus nephritis, versus placebo, meeting the primary endpoint of the phase II NOBILITY trial.1-3 No safety signals were reported.1
Below, we present a visual abstract summarizing a post-hoc analysis of the phase II NOBILITY trial on kidney outcomes with obinutuzumab, presented by Rovin et al.2 at the American College of Rheumatology (ACR) annual meeting (ACR Convergence 2023), and by Rovin et al.3 published in Arthritis Rheumatol. We also include a post-hoc analysis by Vital et al.3 on B-cell recovery with obinutuzumab, presented at the ACR Convergence 2023.
- Rovin BH, Furie RA, Ross Terres JA, et al. Kidney outcomes and preservation of kidney function with obinutuzumab in patients with lupus nephritis: A post hoc analysis of the NOBILITY trial. Arthritis Rheumatol. 2023. DOI:1002/art.42734.
- Rovin B, Ross Terres J, Giang S, et al. Kidney-related outcomes and steroid-sparing effects in patients with active lupus nephritis treated with obinutuzumab: a post hoc analysis of a phase 2 trial. Abstract #784. American College of Rheumatology (ACR) annual meeting (ACR Convergence 2023); Nov 10–15, 2023; San Diego, CA.
- Vital E, Roccatello D, Black D, et al. B-cell recovery in a randomized controlled trial of B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis. Abstract #1511. American College of Rheumatology (ACR) annual meeting (ACR Convergence 2023); Nov 10–15, 2023; San Diego, CA.
Related articles
Newsletter
Subscribe to get the best content related to lupus delivered to your inbox